ArticleBMC veterinary research2026
Characterization and therapeutic evaluation of a novel phage S18-3 targeting poultry-derived Enterobacter hormaechei infection in mice.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEnterobacter hormaechei (E. hormaechei) is an opportunistic pathogen in poultry, increasingly associated with multidrug resistance due to the extensive use of antibiotics in animal production. The emergence of resistant E. hormaechei strains poses a significant threat to poultry health and food safety, highlighting the urgent need for alternative antimicrobial strategies. This study aimed to isolate and characterize a novel lytic bacteriophage targeting E. hormaechei and to evaluate its biological properties and therapeutic potential in a gastrointestinal infection mice model.
resultsA lytic phage, designated S18-3, was isolated from environmental water using E. hormaechei strain HZW1 isolated from diseased broiler liver. Phage S18-3 forms clear plaques (~ 0.6 cm) and exhibits an icosahedral head with a long tail. Optimal infectivity occurs at an MOI of 0.1. S18-3 remains stable from 30 to 50 °C and tolerates a broad pH range (pH 4-11). Whole-genome sequencing revealed no known virulence factors or antimicrobial resistance genes, indicating favorable genetic safety. In a murine intestinal infection model established by antibiotic pretreatment and oral challenge, E. hormaechei caused significant weight loss and mortality. Oral administration of S18-3 markedly improved survival and mitigated weight loss compared with infected controls. Phage S18-3 titers were detectable in feces in infection group, with only transient, low-level presence in blood. Histopathology showed no evident liver injury or inflammatory changes, suggesting no hepatotoxicity associated with phage treatment.
conclusionsPhage S18-3 is a stable, genetically safe lytic phage that effectively alleviates intestinal E. hormaechei infection in a murine model without observable adverse effects. These data support the potential of S18-3 as an antibiotic alternative for controlling E. hormaechei infections in poultry. Further validation in broiler models and farm-level settings is warranted to assess translational applicability in sustainable poultry production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.